Girindus Group and Axolabs announce the launch of a strategic partnership combining their skills and capabilities in oligonucleotide lead optimisation, manufacturing and analytical expertise to offer customers complete service solutions for therapeutic oligunucleotides from early discorvery and preclinical development through clinical stages and into commercialisation. With this initiative, Axolands anand Girindus provide worldwide coustomers engaged in the development of therapeutic oligonucleotides with a seamless and efficient transition from earliy pre-clinical research to the market, managed under the unmbrella of a single long-term partnership.

Axolands offers complete anlaytical and bioanlaytical services as well as small-scale manufacture for a variety of DNA and RNA oligonucleotides. The services also cover all steps from lead identification and optimisation as well as non-GLP pharmacology and early safety assessment.

Girindus is a recognised leader in process development, analytical method development and cGMP manufacturing of oligonucleotide therapeutics from pre-IND development through scale-up to kilogram production, process validation and commercial manufacuring in the FDA inspected plant in Cincinnnati. The portfolio also spans manufacture of small molecule APISs, peptide conjugates and delivery tools as well as radiolabeling services.

The combined service solutions cover the whole therapeutic developmenent chain and elmiate the need to transition processes between vendors, thereby efficiaently reducing timelines, risks, challenges and costs for customers active in drug development and approaching scale-up.

"We are excited to enter into this partnership with Girindus, a leading manufacturer of olignucleotide therapeutics" says Hans-Peter Vornlocker, managing director of research at Axolabs. "We share a mutual understanding on how to best serve customers’ needs and, by combing our expertise, we can help to significantly accelerate timelines and improve the quality of oligonucleotide-based therapeutics."

Marc Lemaitre, CEO of Girindus America and Vorstand of Girindus says, "I’m delighted to cement this alliance with Axolabs. I have known the team in Kulmbach for years, right from the early days of Ribopharma, and I am proud that this experienced team selected Girindus as a partner for GMP work and for commercialisation of their pre-clinical service through our sales channel. Our combined skills and experience provide everyone developing olignucleotide therapeutics with a unique platform covering almost all possible technical needs. This is a significant upgrade in CMO/CRO offering and a great opportunity for our customers."